Overview

Dornase Alpha for the Treatment of COVID-19

Status:
Recruiting
Trial end date:
2020-09-25
Target enrollment:
Participant gender:
Summary
In this study, the effectiveness of the Dornase Alpha treatment, which is known to reduce the viscosity of respiratory secretions, will be investigated in new diagnosed and severe COVID-19 patients separately.
Phase:
Phase 2
Details
Lead Sponsor:
Acibadem University
Collaborator:
The Scientific and Technological Research Council of Turkey